Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury

Launched by LOEWENSTEIN HOSPITAL · Aug 1, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating the effectiveness of two medications, Apixaban and Enoxaparin, in preventing blood clots following a spinal cord injury. Enoxaparin is the standard treatment currently used, but researchers want to see if Apixaban can be a better option during the rehabilitation phase after the injury. Participants in the trial will be given either Enoxaparin or Apixaban for 6 to 12 weeks, depending on the severity of their injury. The researchers will monitor for any blood clots and bleeding events through regular blood tests and ultrasound checks.

To be eligible for this trial, participants must be Hebrew speakers with a spinal cord injury, whether it’s from trauma or not. However, certain health conditions—like active bleeding, severe liver disease, or other serious medical issues—may prevent someone from joining. If you choose to participate, you will receive regular check-ups to ensure your safety and to monitor the effectiveness of the treatment. This study aims to provide valuable insights into the best ways to prevent complications after spinal cord injuries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • spinal cord injury (traumatic of not traumatic), Hebrew speaker.
• Exclusion Criteria:
• • contra-indication for anticoagulant treatment
• • concomitant treatment with any other anticoagulant
• • anticoagulant treatment needed for indications other than VTE prevention following spinal cord injury
• • active clinically significant bleeding
• • any lesion or condition considered a significant risk factor for major bleeding.
• • hepatic disease associated with coagulopathy and clinically relevant bleeding risk
• • pregnancy or breast-feeding
• • heart valve related issues
• • galactose intolerance
• • active cancer
• • patients who require thrombolysis or pulmonary embolectomy
• • patients with renal impairment
• • sensitivity to excipients of the medication
• • anti phospholipid syndrome
• • prosthetic heart valve
• • acute ischemic stroke